[O-02] Oral Session 02

[O-02-2] Myasthenia gravis treatment and outcomes over time - insights from the Japan MG Registry study 2021

Yosuke Onishi¹, Akiyuki Uzawa¹, Manato Yasuda¹, Hiroyuki Akamine¹, Yukiko Ozawa¹, Naoki Kawaguchi¹, Tomoya Kubota², Masayuki Masuda³, Shingo Konno⁴, Naoya Minami⁵, Takashi Kimura⁶, Takamichi Sugimoto⁷, Yasushi Suzuki⁸, Genya Watanabe⁸, Masanori Takahashi², Suzuki Shigeaki⁹, Yuriko Nagane¹⁰, Utsugisawa Kimiaki¹⁰, Satoshi Kuwabara¹ (1.Department of Neurology, Chiba University Graduate School of Medicine, Japan, 2.Department of Clinical Laboratory and Biomedical Sciences, Division of Health Sciences, Osaka University Graduate School of Medicine, Japan, 3.Department of Neurology, Tokyo Medical University, Japan, 4.Department of Neurology, Toho University Ohashi Medical Center, Japan, 5.Department of Neurology, National Hospital Organization Hokkaido Medical Center, Japan, 6.Department of Neurology, Hyogo Medical University, Japan, 7.Department of Clinical Neuroscience and Therapeutics, Hiroshima University, Japan, 8.Department of Neurology, National Hospital Organization Sendai Medical Center, Japan, 9.Department of Neurology, Keio University School of Medicine, Japan, 10.Department of Neurology, Hanamaki General Hospital, Japan)